Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.47 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | PHGDH | O43175 | 4/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1347508 | 0.86 | MEN1 (0.46) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL11230233 | 0.84 | GAA (0.63) | ALDH1A1MAPK1HSD11B1GAATSHR | |
| SCHEMBL10982182 | 0.81 | ALDH1A1 (0.56) | ALDH1A1MAPK1HSD11B1HTTSMN1; SMN2 | |
| SCHEMBL1346520 | 0.81 | ALDH1A1 (0.65) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL7012908 | 0.80 | GAA (0.55) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL11223161 | 0.80 | ALDH1A1 (0.57) | ALDH1A1MAPK1HSD11B1L3MBTL1 | |
| SCHEMBL1346427 | 0.79 | CYP1A2 (0.57) | CA12CA1CA2CA9GAA | |
| SCHEMBL1346552 | 0.78 | CA12 (0.49) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL2070576 | 0.77 | MAPT (0.52) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL8344493 | 0.77 | GAA (0.46) | ALDH1A1CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7906546-B2 | Tetrahydrocarbazoles and derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-03-15 | — | — | US | disclosed |
| US-20100216833-A1 | TETRAHYDROCARBAZOLES AND DERIVATIVES | DEHMLOW HENRIETTA | 2010-08-26 | — | — | US | disclosed |
| US-20090270371-A1 | QUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF MGLUR5 RECEPTOR-MEDIATED DISORDERS | RICHTER GEDEON NYRT. (HU) | 2009-10-29 | — | — | US | disclosed |
| EP-1962849-B1 | QUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF MGLUR5 RECEPTOR-MEDIATED DISORDERS | RICHTER GEDEON NYRT (HU) | 2009-09-30 | — | — | EP | disclosed |
| EP-1732892-B1 | TETRAHYDROCARBAZOLES AND DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-09-17 | — | — | EP | disclosed |
| EP-1962849-A1 | QUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF MGLUR5 RECEPTOR-MEDIATED DISORDERS | Richter Gedeon NYRT (HU) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007072093-A1 | QUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF MGLUR5 RECEPTOR-MEDIATED DISORDERS | RICHTER GEDEON NYRT. (HU) | 2007-06-28 | — | — | WO | disclosed |
| EP-1732892-A1 | TETRAHYDROCARBAZOLES AND DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005092856-A1 | TETRAHYDROCARBAZOLES AND DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-10-06 | — | — | WO | disclosed |
| US-20050215577-A1 | Tetrahydrocarbazoles and derivatives | HOFFMANN-LA ROCHE INC. | 2005-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270371-A1 | QUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF MGLUR5 RECEPTOR-MEDIATED DISORDERS | GRM5, GRIK5, GRM1 | ALDH1A1 2356/4885MAPK1 1268/4885CA12 4670/4885 |
| US-20100216833-A1 | TETRAHYDROCARBAZOLES AND DERIVATIVES | NR1H3, NR1H2, NR1H4 | ALDH1A1 3812/4885MAPK1 2434/4885CA12 4021/4885 |
| US-20050215577-A1 | Tetrahydrocarbazoles and derivatives | NR1H3, NR1H2, NR1H4 | ALDH1A1 3812/4885MAPK1 2434/4885CA12 4021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.